Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Ensifentrine, an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor, can provide additional benefit to existing treatments in patients with Chronic obstructive pulmonary disease (COPD) / Emphysema
Ensifentrine (RPL554) is considered a PDE3/4 inhibitor, although its affinity for PDE3 is 3,440 times higher than that for PDE4, that is under clinical development for the treatment of Chronic obstructive pulmonary disease (COPD) / Emphysema
see also:
Phosphodiesterase inhibitors & Chronic obstructive pulmonary disease (COPD) / Emphysema
…